Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    Ferring Therapeutics Pvt Ltd

    Ferring is a biopharmaceutical company dedicated to the development of innovative treatments that make a real difference in people?s lives all over the world. The company is act

  • No Image
    Fervent Synergies Ltd

    Company was incorporated as a public Limited Company on July 6, 2009, in the name of Fervent Pharma Synergies Limited, under the Companies Act, 1956 and obtained certificate of

  • No Image
    Franklin Laboratories India Pvt Ltd

    Franklin Laboratories (India) Pvt. Ltd. manufactures, trades, exports and supplies a wide array of cough anti-cold preparations, antimicrobial preparations, anti-spasmodic prepa